AGO1x prevents dsRNA-induced interferon signaling to promote breast cancer cell proliferation
Preprint posted on April 10, 2019 https://www.biorxiv.org/content/10.1101/603506v1
Programmed and efficient stop codon readthrough has been initially observed in viruses, but its occurrence has recently been confirmed in other organisms, including humans. Translational readthrough diversifies the proteome by producing low abundant protein isoforms carrying C-terminal extensions. Often, the function of these isoforms differs from that of the canonical protein. The efficiency of translational readthrough depends on a variety of factors. For example, cis-acting elements located in 3’ untranslated region (3’ UTR) of mRNAs can facilitate stop codon readthrough. In the case of the vascular endothelial growth factor A (VEGF-A), binding of the heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1 protein to the 3’ UTR of the mRNA promotes synthesis of an extended isoform dubbed VEGF-Ax (Eswarappa et al, 2014). The same study identified the mRNA of Argonaute 1 (AGO1), a protein well known for its role in RNA-mediated post-transcriptional gene silencing, as a putative target of translational readthrough. However, a thorough characterization of the arising AGO1 isoform was missing so far.
Corroborating the hypothesis that the Argonaute 1 gene is prone to translational readthrough, the authors observed that the region downstream of the AGO1 stop codon is highly conserved across vertebrates. Western blot analysis of AGO1 expression levels in different cell lines revealed a second band of higher molecular weight in addition to the main, expected AGO1 signal. Interestingly, the upper band is more prominent in a breast cancer cell line, compared to the two other cancer cell lines used. Based on these data, the authors speculated that an amplification of the AGO1 locus in breast and ovarian cancer xenografts results in higher translational readthrough of the AGO1 gene. To confirm that the slower-migrating band belongs to a readthrough-dependent AGO1 isoform, the authors raised an antibody directed to the readthrough region of the peptide. With this tool in hand, and supporting their finding with mass spectrometry, the authors convincingly show that translational readthrough takes place on the AGO1 transcript, resulting in the AGO1x isoform.
Unlike canonical AGO1, which resides in the cytoplasm, AGO1x is enriched around the nucleoli, suggesting a different functional role for this isoform. To better understand AGO1x function, two independent mutant cell lines lacking the AGO1x isoform were generated directing the CRISPR/Cas9 system at the predicted readthrough region. Characterizing the mutants, the authors noticed that in absence of AGO1x cell growth and mobility are reduced. Consistently, immunohistochemistry of breast cancer tissues revealed that AGO1x is principally expressed in highly proliferative cells. To define how AGO1x is supporting cell proliferation, the authors analyzed the transcriptome of control and mutant cell lines. RNA sequencing data showed that hundreds of genes are differentially-expressed in AGO1x-deficient cells and these changes are consistent for the two mutant lines. A detailed analysis revealed that expression of genes related to the interferon alpha response and to the apoptosis pathways are increased in the mutant cells relative to control. In line with this observation, treatment with ruxolitinib, an inhibitor of the interferon response fully rescued the growth defect of the mutant cell lines.
By testing their hypothesis that activation of the interferon response in the AGO1x-deficient cells could be due to the accumulation of cytoplasmic double-stranded RNA (dsRNA), the authors demonstrate that the levels of several intracellular dsRNA sensors are increased in the mutant cells compared to the parental cell line. As suggested by the increased amount of dsRNA sensors, higher levels of dsRNA, in particular belonging to rRNAs and GC-rich mRNAs, were detected in the absence of AGO1x. Finally, the Polyribonucleotide nucleotidyltransferase 1 (PNPT1) and the ATP-dependent RNA helicase A (DHX9) were identified as interaction partners of AGO1x. Altogether, these data suggest a role for this newly-discovered complex in sequestering and, possibly, degrading dsRNA. This protective mechanism seems to be particularly important for highly proliferative cells, relying on an increased transcription of ribosomal DNA.
What I like about this work and future direction
It has recently been proposed that cancer cells rely on an alternative translational program, skewed towards oncogenic mRNA translation and sustained translation of upstream open reading frames (uORF). Similarly, the data presented in this paper suggest that translational readthrough could be an additional feature of translational reprogramming of cancer cells. Nevertheless, more data are required to understand if translational readthrough in cancer cells is specifically directed to a subset of genes, as in the case of Argonaute 1, or is a widespread phenomenon.
The authors speculate that amplification of the AGO1 locus in breast and ovarian cancers results in higher expression of AGO1x. Why would this amplification not result in a concomitant increase of the canonical gene product?
Is it possible that increased levels of the heterogeneousribonucleoprotein A2/B1 in cancer cells (or generally in proliferative cells) are responsible for the increment in translational readthrough? Did you compare hnRNP A2/B1 levels between the cell lines used in this study?
Does depletion of hnRNP A2/B1 recapitulate the phenotypes observed in the AGO1x-deficient cell lines?
Is it possible to use the MS data presented in fig. 1e to define which amino acid is used to suppress the stop codon of the AGO1 gene?
Eswarappa SM, Potdar AA, Koch WJ, Fan Y, Vasu K, Lindner D, Willard B, Graham LM, DiCorleto PE, Fox PL. Programmed translational readthrough generates antiangiogenic VEGF-Ax. Cell. 2014 Jun 19;157(7):1605-18.
Posted on: 5th May 2019 , updated on: 7th May 2019Read preprint
Also in the cancer biology category:
Rapid discovery of synthetic DNA sequences to rewrite endogenous T cell circuits
|Selected by||Pavithran Ravindran|
Adipocyte vesicles: ‘all-in-one’ packages that stimulate tumor mitochondrial metabolism and dynamics
|Selected by||Hannah Brunsdon|
Intravital optoacoustic ultrasound bio-microscopy reveals radiation-inhibited skull angiogenesis
|Selected by||Mariana De Niz|
Also in the cell biology category:
Human cardiac fibrosis-on-a-chip model recapitulates disease hallmarks and can serve as a platform for drug screening
|Selected by||Hiroyoshi Y. Tanaka|
Integrated Metabolomic and Transcriptomic Profiling Reveals Novel Activation-Induced Metabolic Networks in Human T cells
|Selected by||Jonny Coates|
Precisely control mitochondria with light to manipulate cell fate decision
|Selected by||Amberley Stephens, Amberley Stephens|
preListscancer biology category:in the
Also in the cell biology category:
Lung Disease and Regeneration
This preprint list compiles highlights from the field of lung biology.
|List by||Rob Hynds|
A curated list of preprints related to cellular metabolism at Biorxiv by Pablo Ranea Robles from the Prelights community. Special interest on lipid metabolism, peroxisomes and mitochondria.
|List by||Pablo Ranea Robles|
BSCB/BSDB Annual Meeting 2019
Preprints presented at the BSCB/BSDB Annual Meeting 2019
|List by||Gautam Dey|
This list of preprints is focused on work expanding our knowledge on mitochondria in any organism, tissue or cell type, from the normal biology to the pathology.
|List by||Sandra Franco Iborra|
ASCB/EMBO Annual Meeting 2018
This list relates to preprints that were discussed at the recent ASCB conference.
|List by||Gautam Dey, Amanda Haage|